View Item 

Show simple item record

TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis
dc.contributor.authorBrown, Andrew M.
dc.contributor.authorKassab, Ihab
dc.contributor.authorMassani, Marco
dc.contributor.authorTownsend, Whitney
dc.contributor.authorSingal, Amit G.
dc.contributor.authorSoydal, Cigdem
dc.contributor.authorMoreno-Luna, Laura
dc.contributor.authorRoberts, Lewis R.
dc.contributor.authorChen, Vincent L.
dc.contributor.authorParikh, Neehar D.
dc.date.accessioned2023-03-03T21:10:57Z
dc.date.available2024-03-03 16:10:55en
dc.date.available2023-03-03T21:10:57Z
dc.date.issued2023-02
dc.identifier.citationBrown, Andrew M.; Kassab, Ihab; Massani, Marco; Townsend, Whitney; Singal, Amit G.; Soydal, Cigdem; Moreno-Luna, Laura ; Roberts, Lewis R.; Chen, Vincent L.; Parikh, Neehar D. (2023). "TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis." Cancer Medicine (3): 2590-2599.
dc.identifier.issn2045-7634
dc.identifier.issn2045-7634
dc.identifier.urihttps://hdl.handle.net/2027.42/175940
dc.description.abstractBackgroundTransarterial radioembolization (TARE) is increasingly used as an alternative to transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC). We aimed to perform an overall and individual patient data (IPD) meta-analysis of studies comparing TACE and TARE.MethodsWe performed a systematic literature search using pre-specified keywords with the aid of an informationist for articles from inception to 3/2020. The primary endpoint was overall survival (OS), and the secondary endpoint was time to progression (TTP).ResultsSeventeen studies met inclusion criteria with 2465 unique patients, with one randomized trial, 4 prospective studies and 12 retrospective studies. Barcelona Clinic Liver Cancer (BCLC) stage B (42.8%) was the most common stage followed by BCLC A (30.3%) and BCLC C (29.0%). There was no difference in OS between the two modalities (−0.55 months, 95% CI −1.95 to 3.05). In three studies with available TTP data, TARE resulted in a longer TTP than TACE (mean TTP 17.5 vs. 9.8 months; mean TTP difference 4.8 months, 95% CI 1.3–8.3 months). IPD-level meta-analysis of 311 patients from three studies showed no difference in overall OS between the two modalities including among subgroups stratified by tumor stage and liver function. Limitations of the current literature include inconsistent length of follow-up, inconsistency in response criteria, and safety reporting.ConclusionsCurrent data suggest TARE provides significantly longer TTP than TACE, although the two treatments do not significantly differ in terms of OS. Given limitations of the current data, there is rationale for prospective studies comparing these modalities.In this overall and individual level meta-analysis, patients with hepatocellular carcinoma treated with transarterial chemoembolization and transarterial radioembolization (TARE) showed similar survival. Patients treated with TARE however, had a longer time to tumor progression.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherlocoregional therapy
dc.subject.otherTACE
dc.subject.otherY-90
dc.subject.otherHCC
dc.titleTACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbsecondlevelHScience : Science (General)ematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175940/1/cam45125.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175940/2/cam45125_am.pdf
dc.identifier.doi10.1002/cam4.5125
dc.identifier.sourceCancer Medicine
dc.identifier.citedreferenceZhang Y, Li Y, Ji H, Zhao X, Lu H. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a meta-analysis. Biosci Trends. 2015; 9 ( 5 ): 289 - 298. doi: 10.5582/bst.2015.01089
dc.identifier.citedreferenceGolfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014; 111 ( 2 ): 255 - 264.
dc.identifier.citedreferenceZhang Z, Fardanesh MR, Machac J, et al. Comparison of therapeutic response using RECIST criteria: Y-90 SIR-spheres and TheraSphere treatment of unresectable hepatocellular carcinoma. Soc Nuclear Med. 2013; 54 ( supplement 2 ): 224.
dc.identifier.citedreferenceMoreno-Luna LE, Yang JD, Sanchez W, et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013; 36 ( 3 ): 714 - 723. doi: 10.1007/s00270-012-0481-2
dc.identifier.citedreferenceSoydal C, Arslan MF, Kucuk ON, Idilman R, Bilgic S. Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona clinic liver cancer stage B-C hepatocellular cancer patients. Nucl Med Commun. 2016; 37 ( 6 ): 646 - 649. doi: 10.1097/MNM.0000000000000486
dc.identifier.citedreferenceMassani M. Yttrium-90 radioembolisation versus transarterial chemoembolisation for unresectable hepatocellular carcinoma: a retrospective comparative analysis according to BCLC classification. Clin Surg. 2017; 2: 1528.
dc.identifier.citedreferenceWan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14: 135. doi: 10.1186/1471-2288-14-135
dc.identifier.citedreferenceLance C, McLennan G, Obuchowski N, et al. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011; 22 ( 12 ): 1697 - 1705. doi: 10.1016/j.jvir.2011.08.013
dc.identifier.citedreferenceKooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2010; 21 ( 2 ): 224 - 230. doi: 10.1016/j.jvir.2009.10.013
dc.identifier.citedreferenceEl Fouly A, Ertle J, El Dorry A, et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int. 2015; 35 ( 2 ): 627 - 635. doi: 10.1111/liv.12637
dc.identifier.citedreferenceAkinwande O, Kim D, Edwards J, et al. Is radioembolization ([90]Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis. Surg Oncol. 2015; 24 ( 3 ): 270 - 275. doi: 10.1016/j.suronc.2015.06.008
dc.identifier.citedreferenceBiederman DM, Titano JJ, Korff RA, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. J Vasc Interv Radiol. 2018; 29 ( 1 ): 30 - 37.e2. doi: 10.1016/j.jvir.2017.08.026
dc.identifier.citedreferenceSalem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011; 140 ( 2 ): 497 - 507.e2. doi: 10.1053/j.gastro.2010.10.049
dc.identifier.citedreferenceAkinwande O, Philips P, Scoggins C, Martin RC. Radioembolization versus chemoembolization (DEBDOX) for the treatment of unresectable hepatocellular carcinoma: a propensity matched study. Anticancer Res. 2016; 36 ( 1 ): 239 - 246.
dc.identifier.citedreferencePitton MB, Kloeckner R, Ruckes C, et al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2015; 38 ( 2 ): 352 - 360. doi: 10.1007/s00270-014-1012-0
dc.identifier.citedreferencePadia SA, Johnson GE, Horton KJ, et al. Segmental Yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. J Vasc Interv Radiol. 2017; 28 ( 6 ): 777 - 785.e1. doi: 10.1016/j.jvir.2017.02.018
dc.identifier.citedreferenceMcDevitt JL, Alian A, Kapoor B, et al. Single-center comparison of overall survival and toxicities in patients with infiltrative hepatocellular carcinoma treated with Yttrium-90 radioembolization or drug-eluting embolic Transarterial chemoembolization. J Vasc Interv Radiol. 2017; 28 ( 10 ): 1371 - 1377. doi: 10.1016/j.jvir.2017.05.017
dc.identifier.citedreferenceShe WH, Cheung TT, Yau TC, et al. Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection. Hepatobiliary Surg Nutr. 2014; 3 ( 4 ): 185 - 193. doi: 10.3978/j.issn.2304-3881.2014.07.09
dc.identifier.citedreferenceCarr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010; 116 ( 5 ): 1305 - 1314. doi: 10.1002/cncr.24884
dc.identifier.citedreferenceAuer TA, Jonczyk M, Collettini F, et al. Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma. Acta Radiol. 2021; 62 ( 3 ): 313 - 321. doi: 10.1177/0284185120926474
dc.identifier.citedreferenceKatsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: a network meta-analysis of randomized controlled trials. PLoS One. 2017; 12 ( 9 ): e0184597. doi: 10.1371/journal.pone.0184597
dc.identifier.citedreferenceCasadei Gardini A, Tamburini E, Inarrairaegui M, Frassineti GL, Sangro B. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther. 2018; 11: 7315 - 7321. doi: 10.2147/OTT.S175715
dc.identifier.citedreferenceChow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018; 36 ( 19 ): 1913 - 1921. doi: 10.1200/JCO.2017.76.0892
dc.identifier.citedreferenceVilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017; 18 ( 12 ): 1624 - 1636. doi: 10.1016/S1470-2045(17)30683-6
dc.identifier.citedreferenceMarqueen KE, Kim E, Ang C, Mazumdar M, Buckstein M, Ferket BS. Cost-effectiveness analysis of selective internal radiotherapy with Yttrium-90 versus sorafenib in locally advanced hepatocellular carcinoma. JCO Oncol Pract. 2021; 17 ( 2 ): e266 - e277.
dc.identifier.citedreferenceParikh ND, Pillai A. Recent advances in hepatocellular carcinoma treatment. Clin Gastroenterol Hepatol. 2021; 19: 2020 - 2024.
dc.identifier.citedreferenceVouche M, Kulik L, Atassi R, et al. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: imaging analysis from a prospective randomized trial of Y90±sorafenib. Hepatology. 2013; 58 ( 5 ): 1655 - 1666.
dc.identifier.citedreferenceGarin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021; 6 ( 1 ): 17 - 29.
dc.identifier.citedreferenceKirchner T, Marquardt S, Werncke T, et al. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma. Abdom Radiol. 2019; 44 ( 4 ): 1554 - 1561.
dc.identifier.citedreferenceSalem R, Gilbertsen M, Butt Z, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013; 11 ( 10 ): 1358 - 1365.e1.
dc.identifier.citedreferenceBray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 ( 6 ): 394 - 424. doi: 10.3322/caac.21492
dc.identifier.citedreferenceSingal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014; 11 ( 4 ): e1001624. doi: 10.1371/journal.pmed.1001624
dc.identifier.citedreferenceMatsumoto MM, Mouli S, Saxena P, et al. Comparing real world, personalized, multidisciplinary tumor board recommendations with BCLC algorithm: 321-patient analysis. Cardiovasc Intervent Radiol. 2021; 44 ( 7 ): 1070 - 1080. doi: 10.1007/s00270-021-02810-8
dc.identifier.citedreferenceMarrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and Management of Hepatocellular Carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68 ( 2 ): 723 - 750. doi: 10.1002/hep.29913
dc.identifier.citedreferenceLlovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359 ( 9319 ): 1734 - 1739. doi: 10.1016/S0140-6736(02)08649-X
dc.identifier.citedreferenceLo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002; 35 ( 5 ): 1164 - 1171. doi: 10.1053/jhep.2002.33156
dc.identifier.citedreferenceSalem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: the LEGACY Study. Hepatology. 2021; 74 ( 5 ): 2342 - 2352.
dc.identifier.citedreferenceEuropean Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69 ( 1 ): 182 - 236. doi: 10.1016/j.jhep.2018.03.019
dc.identifier.citedreferenceHeimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018; 67 ( 1 ): 358 - 380. doi: 10.1002/hep.29086
dc.identifier.citedreferenceSalem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016; 151 ( 6 ): 1155 - 1163.e2. doi: 10.1053/j.gastro.2016.08.029
dc.identifier.citedreferenceMoher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6 ( 7 ): e1000097. doi: 10.1371/journal.pmed.1000097
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cam45125.pdf
Size:
516.5KB
Format:
PDF
View/Open
Name:
cam45125_am.pdf
Size:
4.112MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.